Drug Type Small molecule drug, Diagnostic radiopharmaceuticals |
Synonyms 11C-5-(4-fluorobenzyl)-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]-quinoline |
Target |
Action modulators |
Mechanism GR modulators(Glucocorticoid receptor modulators) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | United States | 10 Aug 2021 | |
Metastatic castration-resistant prostate cancer | Phase 1 | United States | 10 Aug 2021 | |
Metastatic Prostate Carcinoma | Phase 1 | United States | 10 Aug 2021 |